• 3-Deazaadenosine: Methylation Research Context

  2026-10-06

  3-Deazaadenosine is a supplier-described S-adenosylhomocysteine hydrolase inhibitor used to study methylation-dependent biology and preclinical antiviral research. This overview separates that biochemical rationale from findings in a 2024 ulcerative colitis study of METTL14, highlighting what the evidence supports, where comparisons are only conceptual, and why the reported pathway cannot be treated as proof of 3-Deazaadenosine activity.

• Q-VD(OMe)-OPh in Mixed Cell Death Research

  2026-10-06

  Q-VD(OMe)-OPh offers a useful way to interpret caspase dependence when apoptosis overlaps with ferroptosis and autophagy. This evidence-focused guide connects Q-VD-OPh to cetuximab-resistant colorectal cancer research while defining its limits in apoptosis assays, AML differentiation, and neuroprotection.

• Q-VD(OMe)-OPh: Evidence and Limits

  2026-10-05

  A source-grounded overview of Q-VD(OMe)-OPh that explains its caspase-inhibition principle, evaluates the strength of available evidence, interprets its relevance to a colorectal cancer study, and defines important limits for apoptosis research, acute myeloid leukemia differentiation, and neuroprotection in ischemic stroke.

• Potato Virus X as an RNA Delivery Platform

  2026-10-05

  A 2025 Scientific Reports study presents potato virus X coat protein as a modular scaffold for assembling filamentous and halo-shaped nucleoprotein nanoparticles around mRNA and circRNA. The work demonstrates programmable assembly, mixed coat-protein architectures, length control, and reporter-protein expression in eukaryotic cells, while remaining an early proof of concept rather than a validated therapeutic platform.

• SCH772984 HCl: ERK Evidence and Limits

  2026-10-04

  This source-grounded overview explains what SCH772984 HCl can reveal about ERK1/2 and MAPK signaling, how the supplied mouse study connects ERK inhibition with KLF4 and Agrp transcription, and why those findings should not be generalized to human metabolism or cancer treatment.

• Carbapenemase Dynamics in CREC Across Guangdong

  2026-10-03

  A multicenter study of 54 carbapenem-resistant Enterobacter cloacae isolates from eight Guangdong teaching hospitals combined resistance-gene detection, gene-location analysis, transfer assessment, mobile-element profiling, and strain typing. The findings identify plasmid-associated blaNDM-1 as a dominant concern while showing why gene mobility, clonal relatedness, and hospital-level surveillance should be interpreted together.

• β-Elemene Inhibits Adipogenesis via AMPK

  2026-10-01

  The reference study identifies β-elemene as an inhibitor of MDI-induced adipogenesis in 3T3-L1 cells and links this effect to recovery of AMPK-pathway activity. Its integrated lipid, glucose-handling, viability, and gene-expression workflow provides a practical framework for investigating β-elemene and the related name Levo-β-elemene in cellular obesity and insulin-resistance models.

• Acid-Responsive Polymers Improve RNA Transfection

  2026-10-01

  Cheung, Fuchs, and Shoichet developed acid-responsive polymer additives that improve RNA dissociation from lipid nanoparticles after endosomal disruption, rather than primarily increasing uptake or endosomal escape. Hybrid polymer–lipid nanoparticles enhanced siRNA potency and mRNA transfection across cell-based models, providing a practical strategy for improving payload utilization while avoiding more aggressive membrane-disruptive designs.

• Irinotecan: From DNA Damage to Translation

  2026-09-30

  A mechanism-led guide to using Irinotecan and CPT-11 in colorectal cancer research, connecting prodrug activation, assay design, xenograft validation, and the translational implications of chemotherapy-induced nausea and vomiting.

• Rucaparib and the Next Frontier of DDR Signaling

  2026-09-30

  Rucaparib (AG-014699, PF-01367338) offers a mechanistically rich platform for studying PARP1 inhibition, persistent DNA damage, radiosensitization, and context-dependent apoptosis. This thought-leadership perspective connects established DNA repair biology with emerging evidence that RNA Pol II loss can actively signal cell death, while distinguishing validated mechanisms from testable translational hypotheses.

• RSL3–PARP1 Crosstalk in Ferroptosis and Apoptosis

  2026-09-29

  The 2025 study identifies PARP1 as a mechanistic bridge between RSL3-induced ferroptosis and apoptosis, revealing both caspase-dependent PARP1 cleavage and depletion of full-length PARP1 through altered m6A-mediated translation. Its findings connect redox stress, epigenetic RNA regulation, and PARPi-resistant tumor growth, while suggesting that ferroptosis studies benefit from orthogonal measurements of caspase signaling and PARP1 status.

• Dual-Network Microspheres for IVDD Inflammation

  2026-09-29

  The reference study develops PMCCP, an elastic dual-network hydrogel microsphere that combines stimulus-responsive miR-155 delivery with metal-phenolic-network-mediated microenvironment regulation. In vitro and in vivo findings indicate that the platform can reduce inflammatory stress, inhibit nucleus pulposus cell apoptosis, and help restore disc-cell function under degenerative conditions.

• MG-132 Workflows for Proteasome and Apoptosis

  2026-09-28

  MG-132, also known as Z-LLL-al, provides a rapid pharmacologic route for testing how proteasome activity shapes apoptosis, cell-cycle behavior, ROS, and protein stability. This article translates cardiomyocyte findings involving Septin4, VHL, and HIF-1α into practical workflows while emphasizing dose control, pathway-specific controls, and troubleshooting.

• Imatinib (STI571) Workflows for Kinase Research

  2026-09-28

  Build reproducible kinase-inhibition experiments with Imatinib (STI571), from acute phosphorylation readouts to longer cell-proliferation studies. A recent erythroleukemia study also offers a focused way to test imatinib in combination experiments without confusing kinase inhibition with erythroid differentiation.

• Puromycin dihydrochloride: Selection and Translation Guide

  2026-09-27

  Puromycin dihydrochloride provides a way to select pac-expressing cell populations and to perturb protein synthesis in translation-focused experiments. It is not a universal selection dose: establish sensitivity in the target cells, and avoid using it where untreated viability or translation must be preserved.

8836 records 1/590 page Next 12345 下5页 Last page